Breakthrough £90,000 Alzheimer’s drugs unlikely to benefit patients, report suggests

• New anti-amyloid monoclonal antibodies for Alzheimer's disease show clinically minimal benefits despite high cost (£90,000), with disease progression slowing by only 25-35% over 18 months—unlikely to be perceptible to patients or caregivers in practice.
• Major review findings have generated significant controversy within the medical community, suggesting current evidence does not support widespread adoption of these expensive treatments in routine clinical care.
• Prescribers should exercise caution when considering these drugs, carefully discussing realistic expectations with patients and families regarding modest cognitive preservation rather than meaningful functional improvement.

A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.